AI assistant
Opthea Ltd — Board/Management Information 2013
Feb 21, 2013
32698_rns_2013-02-21_6bd1381e-1a24-4519-982c-8689a641a6fe.pdf
Board/Management Information
Open in viewerOpens in your device viewer
ASX and Media release
22 February 2013
==> picture [211 x 55] intentionally omitted <==
Appointment of CFO and Company Secretary.
Circadian is pleased to announce the appointment of Mr Steven Zammit as its Chief Financial Officer and Company Secretary as of February 25 2013.
Mr Zammit is a CPA with a Business Degree from RMIT and a Masters of Banking and Finance from Monash University, with over twenty years of experience in senior finance roles in a range of small and large Australian companies.
He was most recently Chief Financial Officer of the Oliver Hume Real Estate Group for three years and prior to that was General Manager Commercial & Finance and Company Secretary for ASX listed Molopo Energy Limited.
Company enquiries Robert Klupacs Managing Director - Circadian Tel: +61 (0) 3 9826 0399 or [email protected]
About Circadian Technologies Limited
Circadian (ASX:CIR; OTCQX:CKDXY)) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian’s internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for ‘back of the eye’ disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.
Level 1 10 Wallace Avenue Toorak Victoria 3142 Australia
T +61 (3) 9826 0399 F +61 (3) 9824 0083 www.circadian.com.au
ABN 32 006 340 567